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Today the human polyomavirus (HPyV) family consists of 10 members, BK virus (BKV) and JC virus
(JCV) isolated 40 years ago and the more recently identiﬁed KI virus (KIPyV), WU virus (WUPyV),
Merkel cell polyomavirus (MCPyV), HPyV6, HPyV7, trichodysplasia spinulosa virus (TSPyV), HPyV9 and
MWPyV. Serological studies suggest that HPyVs subclinically infect the general population with rates
ranging from 35% to 90%. However, signiﬁcant disease is only observed in patients with impaired
immune functions. Thus, BKV has been linked to hemorrhagic cystitis (HC) after allogeneic hematopoi-
etic stem cell transplantation and PyV-associated nephropathy (PyVAN) after kidney transplantation;
JCV to progressive multifocal leukoencephalopathy (PML) in HIV-AIDS, hematological diseases and in
autoimmune diseases treated with certain lymphocyte-speciﬁc antibodies. KIPyV and WUPyV have
been found in the respiratory tract, HPyV6 and 7 in the skin, and HPyV9 in serum and skin, and MWPyV
in stools and skin, but so far none of these PyVs have been linked to any disease. TSPyV, on the other
hand, was identiﬁed in trichodysplasia spinulosa, a rare skin disease characterized by virus-induced
lytic as well as proliferative tumor-like features that is observed in immune-suppressed transplant
patients. In contrast to all the other HPyVs so far, MCPyV is unique in its association with a cancer,
Merkel cell carcinoma, which is a rare skin cancer arising in the elderly and chronically immunosup-
pressed individuals. The discovery of the new HPyVs has revived interest in the Polyomaviridae and
their association to human disease and cancer. In this review, we summarize knowledge about this
expanding family of human pathogens.
& 2013 Elsevier Inc. All rights reserved.Introduction to human polyomaviruses
Polyomavirus (PyV) infections were accidentally discovered in
the 1950s when characterizing a transmissible agent causing
multiple tumors in rodents, hence providing the name (Greek
poly- many, multiple; -oma, tumors). Gross (1953) described that
ﬁlterable extracts from a mouse leukemia inoculated into new-
born mice could induce tumors in the parotid gland, and the
transforming entity was called the ‘‘parotid agent’’. Stewart and
Eddy later showed that the ‘‘parotid agent’’ was indeed a virus
that could be passaged in tissue culture (Stewart et al., 1958).
It soon became clear that this murine PyV (MPyV) was ubiquitous
in mice, but that tumors only developed in new-born or immu-
nosuppressed mice (Dalianis, 2012; Ramqvist and Dalianis, 2009).
In 1960, the ﬁrst primate PyV was identiﬁed in African green
monkey kidney cells used for the production of polio- and
adenovirus vaccine. This agent was called simian virus 40
(SV40) (Sweet and Hilleman, 1960). Similar to MPyV, SV40 wasll rights reserved.shown to be oncogenic in mice and rodents leading to the concern
that SV40 could also induce tumors in humans following the
distribution of SV40-contaminated vaccines to almost 100 million
individuals by the early 1960s.
Since then, PyVs have been detected in many vertebrate hosts
including birds, rodents, cattle, and humans (Johne et al., 2011;
Krumbholz et al., 2009). Despite being abundant with a highly
conserved structural organization, PyVs have a narrow host and
cell speciﬁcity, which appears to involve restriction on at least
two levels: extracellularly via the presence or absence of recep-
tors to invade the host cell, and intracellularly via the presence or
absence of host cell factors permitting coordinated viral gene
expression and completion of the viral life cycle (Atkin et al.,
2009; Cheng et al., 2009). Experimentally, the restricted host and
cell speciﬁcity can be overcome, and thereby, the risk of onco-
genic transformation is increased, typically at the expense of lytic
replication. Oncogenic transformation is mediated by the PyV
early gene proteins called T (for tumor)-antigens. Key to trans-
formation by PyVs is the genetic or functional uncoupling of
T-antigen expression from the later steps of the viral life cycle
consisting of viral DNA replication, late gene expression,
virion assembly and eventually host cell lysis. Consequent to this
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control by inactivating signal transduction pathways and tumor
suppressors proteins pRB and p53 en route to neoplastic trans-
formation. These concepts have emerged from paradigmatic
research on MPyV and SV40 as DNA tumor viruses (Cheng et al.,
2009). PyVs share several features with papillomaviruses includ-
ing an oncogenic potential, yet are no longer classiﬁed together as
papova, but as the separate genus polyomavirus in the polyoma-
viridae family (Hirsch, 2010).
The ﬁrst two human polyomaviruses (HPyVs) BK virus
(BKV), and JC virus (JCV), were named after the initials of the
patients from whom they were ﬁrst isolated in 1971 (Gardner
et al., 1971; Padgett et al., 1971). From 2007, eight more HPyVs
have been identiﬁed. The third and fourth HPyVs, KI polyoma-
virus (KIPyVV) and WU polyomavirus (WUPyV), were named
after the respective institutions e.g. Karolinska Institute (Stock-
holm, Sweden) (Allander et al., 2007) and Washington Univer-
sity (St. Louis, USA) (Gaynor et al., 2007). The ﬁfth HPyV, MC
polyomavirus (MCPyV), was named due to its detection in
Merkel cell carcinoma (Feng et al., 2008). Likewise, the eight
HPyV, TS polyomavirus (TSPyV), was also named according to
its identiﬁcation in trichodysplasia spinulosa, a rare skin dis-
ease (van der Meijden et al., 2010). HPyV6 and HPyV7, identi-
ﬁed in skin and HPyV9 detected in serum and skin are named in
order of appearance, while the tenth HPyV MWPyV found in
stools and skin was named according to the ﬁrst geographical
location where it was found (Schowalter et al., 2010; Scuda
et al., 2011; Foulongne et al., 2012; Siebrasse et al., 2012; Buck
et al., 2012; Yu et al., 2012). A recent phylogenetic analysis
performed for all HPyVs and other PyVs by Siebrasse et al. (2012) isFig. 1. Phylogenetic analysis of PyVs especially for MWPyV reprinted from Siebrasse
generated using the maximum likelihood method with 1000 bootstrap replicates. Boopresented in Fig. 1. A summary of HPyV seroprevalence in adults is
presented in Table 1. Given the increasing numbers of HPyVs, the
interest in their role in disease and cancer has been revived.Polyomavirus morphology and genome structure
PyVs share a common morphology and structural organization
(Cheng et al., 2009). The virions are small non-enveloped icosahedral
particles of 40–45 nm diameter, with a circular double-stranded DNA
genome of 5 kb wrapped around host cell-derived histones. The
particles are stable enduring high temperatures with little loss of
infectivity (Brodsky et al., 1959). PyV genomes can be divided into
different functional parts as demonstrated in Fig. 2.et a
tstraThe non-coding control region (NCCR) harbors the origin of
replication, the transcription start sites as well as promoter/
enhancer elements with a multitude of seemingly redundant
consensus sequences for DNA binding proteins and transcrip-
tion factors. The NCCR regulates the expression of the viral
early and late genes in concert with the activation and
differentiation state of the host cell. The early gene region encodes the large T-antigen (LTag) and
the small T-antigen (sTag), which are generated from one
major transcript by alternative splicing. LTag and sTag facil-
itate viral genome replication and transformation by e.g.
abrogating cell cycle control. MPyV and hamster PyVs also
encode a third viral early protein called middle T-antigen
(mTag), which shares splice sites with LTag and sTag, and
which also contributes to cell transformation.l. (2012), with permission from the publisher. Amino acid based trees were
p values less than 700 are not shown. (A) VP1; (B) VP2; (C) LTAg.
Table 1
Seroprevalence of HPyVs in adults.
HPyV Seroprevalence
in adults (%)
Country Method References
BKV 82–99 USA, Australia,
Italy
VLP ELISA and VP1 capsomer based ELISA Antonsson et al. (2010), Egli et al. (2009), Kean et al. (2009) and
Viscidi et al., (2011)
JCV 39–81 USA, Australia,
Italy
VLP ELISA and VP1 capsomer based ELISA Antonsson et al. (2010), Egli et al. (2009), Kean et al. (2009) and
Viscidi et al. (2011)
KIPyV 55–90 USA VLP ELISA and VP1 capsomer based ELISA Carter et al. (2009) and Kean et al. (2009)
WUPyV 69–98 USA VP1 capsomer based ELISA Multiplex antibody
binding assays
Kean et al. (2009) and Carter et al. (2009)
MCPyV 60–81 Italy VLP ELISA Multiplex antibody binding assay Carter et al. (2009) and Viscidi et al. (2011)
HPyV6 69 USA VLP ELISA Schowalter et al. (2010)
HPyV7 35 USA VLP ELISA Schowalter et al. (2010)
TSV 70 The
Netherlands
Multiplex antibody binding assay van der Meijden et al. (2010)
HPyV9 21–53 France,
Germany
VLP ELISA VP1 recombinant protein ELISA Nicol et al. (2012) and Trusch et al. (2012)
MWPyV/
HpyV10
NDn
n Not done.
Fig. 2. Scheme of a prototype PyV genome showing closed circular, double-
stranded DNA (black circle), the non-coding control region (NCCR), the primary
transcripts of the viral early and late genes (blue arrows), and the spliced major
messenger RNA of the early proteins large and small T-antigen (red arrows, open
reading frame (ORF), solid line; intron, dotted line), and capsid proteins VP1, VP2,
and VP3 (green arrows) including the small ORF encoding the agnoproteins in
BKV, JCV, and SV40. Minor spliced transcripts for smaller derivatives of the large
T-antigen or the VP4 are not indicated. Also, proven or predicted microRNAs such
as the one present in the late transcripts overlapping and hence targeting the large
T-antigen transcript are not indicated. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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VP-3 generated from a primary transcript by alternative
splicing and assembled in the nucleus to form the PyV capsid,
where VP1 dominates (roughly 90% of the molecules) making
the outer shell. In addition, the late region of BKV and JCV (and
SV40) encodes a small non-structural protein called agnopro-
tein upstream of the VP1 coding region which is not found in
any of the other currently known HPyVs (Jay et al., 1981;
Okada et al., 2001; Rinaldo et al., 1998). Multiple roles have
been attributed to this small cytoplasmic protein, but its key
function is presently unclear (Khalili et al., 2005; Unterstab
et al., 2010).
As mentioned above there is a high degree of homology among
PyVs at the nucleotide level and at the amino acid level ranging
from 50% to more than 80% and the homology is generally higher
for the viral early genes as compared to the viral capsid proteins.
Nevertheless, PyVs show both host and cell speciﬁcity (Atkin
et al., 2009; Cheng et al., 2009).Concepts of human polyomavirus pathology
HPyV infections are prevalent in the general population, but
rarely cause clinically apparent disease or pathology. However,
where apparent, their associated pathologies differ, likely a result
of the relative contributions of viral replication and host response.
Five different pathology patterns have been described (Hirsch,
2005) as described below: Cytopathic PyV pathology pattern is characterized by the loss of
infected cells through high-level virus replication, but without
signiﬁcant inﬂammation. The prototype of this pathology is
progressive multifocal leukoencephalopathy (PML) caused by
immunologically uncontrolled JCV replication in the brain of
patients with advanced HIV-AIDS. The cytopathic loss of the
infected oligodendrocytes is sufﬁcient to explain the neurolo-
gical deﬁcits, the neuroradiological ﬁndings, and disease pro-
gression. Recently, however, signs of inﬂammation have been
described in PML cases with residual immune activity (see
immediately below). Immune-reconstitution inﬂammatory syndrome (IRIS) is a PyV
pathology characterized by a dominant inﬂammatory response
to abundant PyV antigen, typically following a brisk recovery
of the cellular immune response (Binet et al., 2000; Hirsch,
2005). The prototypes are BKV-associated hemorrhagic cystitis
(HC) after allogenic stem cell transplantation or the paradox-
ical worsening of PML after the start of combination antire-
troviral therapy for HIV-AIDS (Safdar et al., 2002), or following
removal of natalizumab by plasmapheresis in multiple sclero-
sis patients (Kappos et al., 2007). Cytopathic-inﬂammatory PyV pathology is characterized by
high-level virus replication and a signiﬁcant inﬂammatory
response due to cytopathic lysis, necrosis, with inﬁltration of
granulocytes and lymphocytes. The prototype of this pathol-
ogy pattern is seen as polyomavirus associated nephropathy
(PyVAN) stage B in kidney allografts. Autoimmune PyV pathology, and particularly systemic lupus
erythematosus (SLE) has been proposed to result from a patho-
logic response to ‘‘self’’ which may be triggered by viral antigens.
Examples include LTag complexed to DNA and nucleosomes,
which may induce DNA-antibodies, anti-histone antibodies or
possibly other antinuclear antibodies (Bredholt et al., 1999;
Fredriksen et al., 1994; Mortensen et al., 2008). Oncogenic PyV pathology is characterized by viral early gene
expression activating the host cells, but without sufﬁcient late
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oncogenic PyV pathology is MCPyV-associated Merkel cell
carcinoma, where viral genome replication and late gene
expression is impaired due to chromosomal integration and
truncating mutations in the LTag and/or VP1 (Feng et al.,
2008). Uncoupling of LTag expression from capsid expression,
virion assembly and cell lysis may also be involved in rare
cases of BKV-associated urothelial cancers (Geetha et al.,
2002). Immunologic recognition of speciﬁc LTag epitopes is
known to be protective in experimental cancer models with
MPyV or SV40 (Ramqvist and Dalianis, 2009; Schell et al.,
2001) suggesting that immunologic deﬁcits most likely play a
role in oncogenic PyV pathology in humans.
The different types of PyV pathology are predicted to arise due
to different underlying processes that are driving the disease
(Hirsch, 2005; Hirsch, 2010; Hirsch and Steiger, 2003). Accord-
ingly, increasing or high viral loads must be relevant markers in
entities associated with high-level replication such as PyVAN,
PML and hemorrhagic cystitis. Conversely, autoimmune or onco-
genic pathology is formally no longer dependent on concurrent
lytic PyV replication. Whether or not PyV DNA or proteins can be
measured, further interpretation of the data is complicated by
potentially false-negative as well as false-positive results, not
merely in the analytical sense, but also in the conceptual sense
where ‘‘hit-and-run’’, ‘‘passenger’’ versus ‘‘driver’’ versus ‘‘inno-
cent by-stander’’ signals must be distinguished. Obviously, this
becomes even more difﬁcult once patients have been treated with
immunosuppressive drugs or chemotherapy, conditions that favor
‘‘by-stander’’ PyV reactivation.The role of human polyomaviruses in cancer
The etiologic contribution of PyV is suggested to represent
mechanistically a ‘‘driver’’ role to a given cancer, but this can be
challenged in three ways: by the ‘‘hit-and-run’’ mechanism, where PyV infection con-
tributed at an early stage to oncogenic progression e.g. by
chromosomal instability, but PyV is no longer detectable after
full progression to malignancy when diagnosis is made; by the ‘‘passenger’’ PyV that ﬁnds favorable conditions in an
already transformed cell, but is neither necessary for, nor
contributing to, its oncogenic characteristics, by the ‘‘by-stander’’ PyV that infects neighboring cells or is
detectable in anatomically connected compartments, but is
unrelated to the malignancy.
True clonally integrated or episomal PyV DNA in a histologi-
cally diagnosed cancer may be a tumor marker similar to Epstein-
Barr virus in posttransplant lymphoproliferative disease (Funk
et al., 2008). Here, care has to be taken that PyV sequences are not
missed, and to target several sequences encoding the relevant
transforming domains of LTag. Of note, some presentations
appear mixed with respect to the pathology patterns outlined
above and for example limited lytic PyV replication can be
observed in transformed cells (Haycox et al., 1999; Rinaldo
et al., 2003; van der Meijden et al., 2010; Wetzels et al., 2009).
BKV and JCV
Following the isolation of BKV and JCV in 1971 (Gardner et al.,
1971; Padgett et al., 1971), seroprevalence studies indicated early
and high exposure to BKV, with rates of more than 50% among
2-year-old children increasing to more than 90% among the morethan 10-year olds (Antonsson et al., 2010; Egli et al., 2009; Kean
et al., 2009; Knowles et al., 2003; Lundstig and Dillner 2006; Shah
et al., 1973; Stolt et al., 2003). JCV seroprevalence increases more
slowly, and typically later than that for BKV infection, reaching
50–70% or more, among older healthy adults (Antonsson et al.,
2010; Egli et al., 2009; Knowles et al., 2003). Together, the data
support the notion that signiﬁcant exposure to JCV occurs during
adult life and implicates certain behavioral or environmental risk
factors yet to be identiﬁed.
The route of transmission has not been clariﬁed, since primary
BKV or JCV infections are presumably subclinical. Contact of
virus-bearing ﬂuids and secretion with mucosal surfaces is gen-
erally assumed, but contaminated food and water have also been
suggested as sources of infection (Boﬁll-Mas et al., 2001; Boﬁll-
Mas and Pina, 2000). Subsequently, however, BKV and JCV are
known to persist in the reno-urinary tract (Chesters et al., 1983).
Therefore, a viremic phase must be postulated, where various
cells and organs may be exposed to either virus (Hirsch and
Steiger, 2003). Urinary shedding has been reported to occur
asymptomatically and intermittently in healthy individuals, with
JCV viruria somewhat more common and with a higher load than
BKV viruria (Egli et al., 2009; Hirsch and Steiger, 2003; Polo et al.,
2004). In situations of altered immune function including preg-
nancy, the rates and levels of urinary BKV shedding typically
increase more dramatically than those for JCV, and urine cytology
can appear as shedding of tubular epithelial or urothelial cells
with intranuclear viral inclusion called ‘‘decoy cells’’ (Barton et al.,
2006; Drachenberg et al., 2007; Funk et al., 2008; Gosert et al.,
2008; Randhawa et al., 2005). Despite high urine viral loads,
symptoms are absent in most solid organ transplant patients
suggesting that the cytopathic wear in the urothelial ampliﬁca-
tion compartment is well compensated.
Signiﬁcant organ disease is observed only in patients with
speciﬁc cofactors such as kidney transplantation for nephropathy
(Binet et al., 1999; Hirsch et al., 2002; Nickeleit et al., 2000), or
allogenic stem cell transplantation for hemorrhagic cystitis
(Arthur et al., 1986; Bogdanovic et al., 2004; Giraud et al., 2006;
Giraud et al., 2008a), or HIV-AIDS or multiple sclerosis treated
with natalizumab for progressive multiﬁcal leukoencephalopathy
(Berger et al., 1987; Gosert et al., 2010; Khanna et al., 2009;
Hellwig and Gold 2011; Hirsch, 2010; Maginnis and Atwood
(2009)). Interestingly, nephropathy due to JCV is rare, and JCV
viremia is close to the limit of detection despite an apparently
similar opportunity for reactivation with frequent and high urine
viral loads. Conversely, BKV-associated PML or encephalitis is rare
(Behzad-Behbahani et al., 2003; Jorgensen et al., 2003; Vallbracht
et al., 1993), arguing strongly that BKV and JCV possess signiﬁcant
biological differences, despite their close homology.
A role for BKV and JCV in malignant transformation was
proposed early after their initial isolation in 1971 (Gardner
et al., 1971; Padgett et al., 1971; Walker et al., 1973). Inoculation
into newborn rodents induced diverse neoplasias including brain
tumors and sarcomas as had been observed for MuPyV and SV40
(Ramqvist and Dalianis 2009; zur Hausen, 2008; Dalianis and
Hirsch, 2012). In vitro studies supported the oncogenic contribu-
tion of their LTag and sTag with the potential to cooperate with
other oncogenic alterations. Despite the suggestive mechanistic
evidence, the role of BKV and JCV in human malignancies is
controversial. The high seroprevalence and high detection rate of
BKV and JCV by sensitive molecular tools in healthy individuals
complicates studies and require a rigorous re-evaluation of the
published data. For BKV, the most convincing data of an onco-
genic contribution have been presented in single case reports of
urothelial malignancies and renal tubular malignancies, typically
in the setting of kidney transplantation as illustrated by three
reported single cases: (Emerson et al., 2008; Geetha et al., 2002;
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convincingly in such tumors (Kausman et al., 2004; Loghavi and
Bose, 2011). These reports show the complexity of the ﬁeld and
the need to conduct larger studies using stringent, extensive
protocols which best include several complementing diagnostic
procedures. There are also reports on the detection of BKV DNA in
other tumors, e.g. colorectal tumors, lymphomas, pancreatic
cancer, brain tumors, prostate cancer and a range of sarcomas
(Abend et al., 2009a), and for and for non-UV light associated
melanomas (Giraud et al., 2008b). The interpretation of the data
in these reports have been various and controversial. However,
based on ‘‘inadequate evidence’’ in humans and ‘‘sufﬁcient evi-
dence’’ in experimental animals, a WHO International Agency for
Cancer Research Monograph Working Group recently classiﬁed
BKV and JCV as ‘‘possibly carcinogenic to humans’’ (Group 2B),
(Bouvard et al., 2012).KIPyV and WUPyV
KI andWU polyomaviruses were both reported in 2007, almost
40 years after the ﬁrst two HPyVs were described (Allander et al.,
2007; Gaynor et al., 2007). KIPyV and WUPyV were detected by
similar molecular techniques, and not by in vitro culture as
previously used for detection of PyVs (Allander et al., 2007;
Gaynor et al., 2007). KIPyV was discovered in a screen for viruses
in nasopharyngeal aspirates (NPA) from children with respiratory
tract infections (Allander et al., 2007). The isolation technique
included concentration of the samples using ﬁltration and ultra-
centrifugation, followed by DNase digestion, assuming that viral
genomes would be protected by this procedure. Using random
primers and PCR, the residual nucleic acid was ampliﬁed, the
products cloned and subjected to high throughput DNA sequen-
cing followed by bioinformatic analysis. A clone with homology to
SV40 VP1 was found, and with new speciﬁc primers the entire
viral genome of KIPyV was isolated (Allander et al., 2007).
In a similar way, WUPyV was detected from a NPA of a child
with pneumonia (Gaynor et al., 2007). Also here, nuclease treat-
ment, random primer PCR ampliﬁcation and cloning, high
throughput DNA sequencing, and bioinformatics were used. In
this case, three clones had some homology to JCV, BKV, and SV40,
and after further PCR ampliﬁcation the full genome sequence of
WUPyV was generated.
Both WUPyV and KIPyV were classiﬁed as PyV through
sequence homology (Allander et al., 2007; Gaynor et al., 2007).
They both had coding regions for LTag and sTag, and VP1-3. Their
LTag proteins had domain homologies similar to other HPyVs,
with a DnaJ, pRb binding, viral origin binding, helicase, and also
suggest ATPase-p53 binding domains. Both WUPyV and KIPyV
lacked mTag and the agnoprotein. Phylogenetically, the two
viruses group together in a new branch of the polyomavirus
family (Dalianis et al., 2009).
The ﬁrst prevalence data for WUPyV and KIPyV were based on
PCR detection of virus DNA in NPA samples and it was obvious
that these viruses were widespread globally. Their prevalence in
healthy individuals varied from 0.5–5% for KIPyV and 0.4–9% for
WUPyV, and this difference did not increase for patients with
respiratory symptoms, while their prevalence increased in immu-
nosuppressed individuals in some, but not all reports (Ren et al.,
2008; van der Zalm et al., 2008; Rao et al., 2011). Furthermore,
ELISA tests for VP1 antibodies showed that exposure to both
WUPyV and KIPyV is common (55–98%), and suggests that initial
exposure arises during childhood (Carter et al., 2009; Dalianis
et al., 2009; Kean et al., 2009; Nguyen et al., 2009).
In parallel, other studies used similar methods as above to look
at the prevalence of the KIPyV and WUPyV at other sites than therespiratory site, e.g. in urine, blood and stool (Abedi Kiasari et al.,
2008; Dalianis et al., 2009; Ren et al., 2009). KIPyV and WUPyV
genomic DNA monitored for by PCR detection was not commonly
detected in the urine of normal or immunosuppressed indivi-
duals, or in the blood, but WUPyV could be found at very low
frequency (o1%) in stool samples (Allander et al., 2007; Gaynor
et al., 2007; Ren et al., 2009). Also, KIPyV or WUPyV were not
found in cerebrospinal ﬂuid (CSF) of patients with or without PML
(Dang et al., 2011). So far taken together, these prevalence studies
do not link KIPyV or WUPyV to any human disease.
Several studies have investigated whether KIPyV or WUPyV
are involved in tumor development and so far the results have
been negative for childhood brain tumors, and non-UV exposed
melanomas (Giraud et al., 2009; Giraud et al., 2008b). In one
study KIPyV VP1 DNA was detected in 9/20 lung cancer cases of
undeﬁned origin and in 2/2 transplant patients (Babakir-Mina
et al., 2009). Only the C-terminal domain of the early region of
KIPyV was successfully identiﬁed in two of the lung tissues, and
possible integration was not analyzed. Thus, there is no compel-
ling evidence to date for a role of KIPyV in oncogenesis, although
the data may indicate the lung as a site of viral persistence.MCPyV
To identify MCPyV, a ‘‘digital transcriptome subtraction’’ was
used, where cDNAs were made from target cell transcripts, in this
case from Merkel cell carcinoma, a rare neuroendocrine skin
tumor observed in elderly or immunosuppressed patients (Feng
et al., 2008). These transcripts were then subjected to DNA pyro-
sequencing, with subsequent bioinformatic screening of the data
to identify non-human transcripts (Feng et al., 2008). Of the
almost 400,000 analyzed sequences, one showed homology to
LTag sequences of LPV and BKV, and the full-length clone was
named Merkel cell polyomavirus (MCPyV). Notably, this viral
DNA was integrated into the host cell genome.
In the original study, prototypes MCPyV 350 and 339 were
cloned, and they differed primarily in the LTag gene, although
minor differences were also present in VP1 (Feng et al., 2008). Of
the 10 Merkel cell tumors that were then screened by PCR, 8 were
MCPyV positive, and 5 of these showed clonal hybridization
patterns by Southern blot. Again, since MCPyV was classiﬁed as
PyV through sequence homology, its similarity to other PyV
members was expected. It contains coding regions for LTag and
sTag, and VP1-3, but not for the agnoprotein (Feng et al., 2008). Its
LTag has homologies to that described for other PyVs with a DnaJ,
pRb binding sequence, viral origin binding, helicase, and suggests
also p53 binding domains. MCPyV lacks a ‘‘host-range’’ domain at
the carboxy terminus of LTag, but has an analog to the 17k Tag
transcript of SV40 and BKV (Abend et al., 2009b; Feng et al., 2008;
Zerrahn et al., 1993).
By the time MCPyV was identiﬁed, the methodology to detect
seroreactivity had been further reﬁned and prevalence data for
MCPyV could be rapidly obtained by serology (Kean et al., 2009;
Carter et al., 2009). It became clear that MCPyV was widely
distributed worldwide and that seroprevalence in general against
MCPyV was high (Pastrana D et al., 2009). Children were found to
have antibodies against MCPyV, although to a lower extent (10%),
indicating some exposure to MCPyV already during childhood.
Further studies on the prevalence of MCPyV DNA sequences in
normal tissues have also conﬁrmed the presence of MCPyV in
NPA, in saliva and in the gut of healthy individuals and in the
blood of immunosuppressed individuals, but infrequently in CSF
of patients with and without PML (Dang et al., 2011; Loyo et al.,
2010; Schowalter et al., 2010; Wieland et al., 2009).
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tumors. First of all, MCPyV sequences were identiﬁed in 8/10, and
integrated in 5/8 MCCs as mentioned above, thus immediately
linking MCPyV to the pathogenesis of MCC (Feng et al., 2008). This
study was followed by others again detecting MCPyV in around
80% of the MCC samples and it was disclosed that the LTag was
frequently truncated before the helicase domain (Duncavage
et al., 2009). In addition, deletions of the VP1 region were also
reported (Sharp et al., 2009). These data are in line with earlier
ﬁndings regarding the oncogenic SV40 and MuPyV, and support
the hypothesis that MCPyV in MCC loses its DNA replication
capacity during integration by selective mutations of VP1 or
deletions of LTag, while its transformation ability remains intact
(Shuda et al., 2009).
The presence of MCPyV was been examined in other tumors,
particularly those of the skin. MCPyV DNA was detected by PCR
signiﬁcantly more often in non-melanoma skin cancer (squamous
cell carcinoma, basal cell carcinoma and Bowens Disease) in immu-
nosuppressed patients as compared to non-immunosuppressed
patients (Kassem et al. 2009). MCPyV DNA was however not detected
by PCR in 38 extracutaneous melanomas samples by PCR (Giraud
et al., 2009). MCPyV DNA was nevertheless detected in keratoa-
canthoma or squamous cell carcinoma, but then viral loads were two
orders of magnitude lower compared with that of MCPyV in MCC
(Wieland et al., 2012). The presence of MCPyV DNA was investigated
in ﬁve patients with MCC and ten patients with small cell lung
carcinoma (SCLC), both tumors being small neuroendocrine carcino-
mas, but only found in 2/5 MCCs (Wetzels et al., 2009). Furthermore,
the oncogenic role of MCPyV in 25 childhood brain tumors and 30
lung cancer cases was examined, and in 28 prostate cancer samples,
and although the numbers of cases were limited there was no
evidence of MCPyV DNA in these tumors (Giraud et al., 2008b;
Bluemn et al., 2009). In addition, MCPyV was not found in Guthrie
cards of children that later developed leukemia (Gustafsson et al.
2012). Finally, in a much larger study of 1241 tumors using PCR,
MCPyV sequences were found in 10 MCCs, but not in melanoma,
basal cell carcinoma, uterine cervix, large bowel, ovary, breast, bone,
and soft tissue tumors (Sastre-Garau et al., 2009).
Thus, there is so far little evidence that MCPyV plays a role in
the oncogenesis of tumors other than MCC. On the hand, the role
of MCPyV in MCC is further supported by the fact that MCC is
addicted to Tag expression and that MCC patients frequently have
very high antibody titers to MCPyV as compared to the population
in general, indicating that MCPyV infection indeed is associated to
MCC (Pastrana et al., 2009).HPyV6 and HPyV7
The fact that MCPyV was detected in the skin prompted
Schowalter et al. (Schowalter et al., 2010) to investigate if MCPyV
could be detected in the skin of the forehead as mentioned above.
Rolling circle ampliﬁcation (RCA) was used (Schowalter et al.,
2010) followed by the use of restriction enzymes expected to cut
MCPyV and this resulted in a smoothly distributed smear on the
agarose gel. To overcome this problem the authors used a
preprocessing step, where the extracted DNA was digested with
exodeoxyribonuclease V, an enzyme that digests linear DNA
molecules, sparing double stranded circular DNA molecules
(Schowalter et al., 2010). This way it was possible to identify
MCPyV in 14/35 (40%) of the swabs from healthy volunteers. In
addition, when sequencing, two completely new HPyVs were
identiﬁed, HPyV6 and HPyV7. HPyV6 was identiﬁed after sequen-
cing a 1.6 kb BamHI fragment from the initial RCA analysis.
HPyV7 sequence, on the other hand, emerged using a degenerate
pair of PCR primers, that could bind both HPyV6 and WUPyV, andhad 68% homology to HPyV6 (for details, see Johne et al., 2009).
The degenerate primers that were used did not identify sequences
beyond MCPyV, HPyV6 and HPyV7. HPyV6 and HPyV7 were found
in 5/35 and 4/35 skin samples, respectively, however, HPyV6 and
HPyV7 were not found in MCPyV negative MCC (Duncavage and
Pfeifer, 2011). Complete phylogenetic comparison of HPyV6 and
HPyV7 showed that these occupy a distinct clade, but also share a
common branch with KIPyV and WUPyV (Schowalter et al., 2010).
This afﬁliation is due to the extreme divergence of the late regions
of these four species as compared to all other PyVs. However, the
early region of HPyV6 and HPyV7 are distinct from those of KIPyV
and WUPyV.
Seroprevalence studies in 95 serum samples, previously inves-
tigated for antibodies to other polyomaviruses (Pastrana et al.,
2009; Tolstov et al., 2009) showed that seroreactivity against
HPyV6 was common with 69% of the samples being seropositive,
while seroprevalence towards HPyV7 was 35% ( Schowalter et al.,
2010). There is no evidence for a correlation between HPyV6 and
HPyV7 and disease, or malignant transformation so far, but
obviously additional investigations are necessary.TSPyV
Already in 1999, Haycox et al. demonstrated the intracellular
presence of virus particles in cells from a patient with trichodys-
plasia spinulosa, a rare skin disease in immunosuppressed
patients characterized by papules and spines and alopecia in the
face (Haycox et al., 1999). However, it was not until 2010 that the
identiﬁcation of a new human polyomavirus (TSPyV) in plucked
facial spines of a heart transplant patient with trichodysplasia
spinulosa was reported as the eighth HPyV to be identiﬁed (van der
Meijden et al., 2010). Likewise, TSV was conﬁrmed in trichodysplasia
spinulosa in another report (Matthews et al., 2011).
For detection of TSPyV, spicules were collected from the nose,
dissolved in lysis buffer and subjected to nucleic acid extraction.
The extracted material was then used as a template for rolling
circle ampliﬁcation (RCA), where the DNA dependent F29poly-
merase, an enzyme that preferentially ampliﬁes circular DNA was
used (Johne et al., 2009). The obtained product was cut with
restriction enzymes and further analyzed by gel electrophoresis
and based on the size of the fragments the amplicon was
estimated to be around 5000 bp. These fragments were subse-
quently sequenced and a 5232 bp circular DNA sequence was
obtained that resembled a PyV. It had a NCCR, an origin of
replication, and three putative late genes VP1-3. In addition, the
putative TSPyV expressed LTag and sTag from a common primary
transcript subject to alternative splicing. Its LTag had character-
istic motifs such as the J-domain, the ori DNA-binding domain, an
ATPase/helicase domain including a sequence that corresponde to
the putative p53-binding domain, and also pRb family-binding motifs,
potentially involved in cellular transformation (Schowalter et al.,
2010). Phylogenetic analysis involving VP1, 2 and LTag, showed
resemblance of TSPyV to Borneo Orangutan polyomavirus, and
support the classiﬁcation of TSPyV as a new PyV species rather than
a strain of the already known ones (van der Meijden et al., 2010).
In the above study, attempts were made to ﬁnd TSPyV in other
immunosuppressed patients not suffering from trichodysplasia
spinulosa, and TSPyV was found in plucked eyebrows of 3/69 (4%)
examined patients. However, TSPyV was not detected in 5 JCV
positive cerebral spinal ﬂuids, or 20 BKV positive blood plasma or
in 20 KI or WU positive NPAs. Later, it was shown, by a Luminex
based TSV VP1 immunoassay, that the overall TSV seropreva-
lence in 528 healthy persons in the Netherlands was 70%
(range 10% in small children to 80% in adults) (van der Meijden
et al., 2011).
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spinulosa. Its presence and high seroprevalence in clinically
healthy persons suggests that it causes a subclinical latent
infection. Whether TSV is involved in other diseases or tumors
remains to be investigated.HPyV9
HPyV9 was detected in the serum of a renal transplant patient
(Scuda et al., 2011). The goal of the study was to identify possible
new HPyVs associated with opportunistic infections in immuno-
suppressed patients. The approach started with extracted DNA
from 597 clinical samples, (e.g. serum, plasma, urine or whole
blood) originally taken for BKV and herpesvirus diagnostics from
immunosuppressed transplant patients, PML or HIV patients in
three German hospitals. In addition, CSF from PML patients, or
bronchoalveolar lavage (BAL) ﬂuid from patients with pneumonia
and feces from children with diarrhea were collected. A so-called
generic PCR assay using degenerate and deoxinosine-substituted
primers described previously was used (Scuda et al., 2011). The
primers had been designed to target conserved regions in the VP1
sequences of the known PyVs, with the exception of the highly
divergent PyVs such as KIPyV, WUPyV, HPyV6 and HPyV7
(Leendertz et al., 2011). This way, and by sequencing and BLAST
analysis (Scuda et al., 2011), the authors could identify VP1
sequences from known PyVs in 84 of 597 samples. BKV domi-
nated (n¼56), followed by JCV (n¼18), MCPyV (n¼8) and TSV
(n¼2). These known PyVs were found in plasma, urine and BAL,
but not in CSF, whole blood, serum or feces. In addition, an
unknown PyV sequence was ampliﬁed from the serum of a kidney
transplant patient under immunosuppressive treatment. BLAST
analysis revealed the closest similarity to the VP1 gene of African
green monkey-derived lymphotropic polyomavirus (LPV). A
950 bp sequence spanning parts of the VP3 and VP1 genes was
further ampliﬁed (for further details see Altschul et al., 1990), and
based on the resulting sequence, primers designed tail to tail for
the ampliﬁcation and sequencing for the remaining part of the
genome were used.
HPyV9 was determined to have a 5026 bp long genome with
high similarity to LPV. The close relationship between the two
viruses was conﬁrmed by phylogenetic analysis. HPyV9 exhibited
the presence of an NCCR, putative coding regions for VP1-3, LTag
and sTag. HPyV9 had highest similarity as well as identical amino
acids, to LPV with regard to the J-domain, the RB binding domain,
the Ori-binding domain as well as the Zinc ﬁnger domain.
Using an HPyV9-speciﬁc nested PCR, all 597 samples were
rescreened and in four additional samples (serum, plasma, whole
blood and urine), VP1 sequences from HPyV9 were detected. The
authors could by additional analyses further qualify HPyV9 as a
human virus, although one with low prevalence in the selected
samples (Scuda et al., 2011). More recently, it has been shown
that HPyV9 also resides in the skin (Foulongne et al., 2012;
Sauvage et al., 2011). Nevertheless, additional, studies may be
necessary to identify possible other sites of HPyV9 replication and
persistence, and its role, if any, in human cancer and disease.
The fact that HPyV9 shows close relatedness to lymphotropic
polyomavirus (LPV) found in African Green Monkey is of special
interest. For long it has been known that around 30% of adult
human sera contain antibodies to LPV, and the search for LPV in
humans has been elusive (Brade et al., 1981; Kean et al., 2009;
Scuda et al., 2011). The identiﬁcation of HPyV9 has now revealed
a potential human LPV counterpart that can explain this remark-
able serological cross-reactivity and recently it has been shown
that the seroprevalence of HPyV 9 is roughly 21–53% (Nicol et al.,
2012; Trusch et al., 2012). However, additional studies to furtherelucidate the remarkable relationship between the two viruses
could be of interest.
MWPyV (HPyV10, MXPyV)
MWPyV was identiﬁed by shotgun pyrosequencing of DNA
puriﬁed from virus-like particles isolated from a stool sample
collected from a healthy child from Malawi (Siebrasse et al. 2012).
Its 4927 bp genome was subsequently sequenced and was predicted
to encode an LTag, a sTag and VP1-3. A real time PCR assay was then
designed and used to screen 514 stool samples from children with
diarrhea in St Louis, USA. MWPyV was detected in 12 of these
samples, but the index strain of these samples differed by 5.3% at
the nucleotide level compared to the Malawi index case.
In parallel, using RCA-based analysis of chondyloma specimens
from a patient with warts with hypoglobulinemia, infections, and
myeloathexis (WHIM) syndrome an HPyV was detected named
HPyV10 (Buck et al., 2012). Upon sequencing nucleotide analysis of
the MWPyV isolates (assession numbers JQ898291 and JQ898292)
shows that they are 95% to 99% identical to HPyV10, thus likely the
same virus. Whether HPyV10 was responsible for the warts or
associated to any other disease or cancer was not been addressed,
but most probably unlikely, since the sample also contained the
papilloma causing human papillomavirus (HPV) type 6.
Finally, very recently, in stools of children an HPyV designated
MXPyV was described (Yu et al., 2012). This virus is a closely
related variant of MWPyV and HPyV10, and the study thus
conﬁrmed that this tenth HPyV can frequently be found in stools.
However, whether the virus elicits a chronic infection in the
gastrointestinal system, or is responsible for any disease in
humans has yet to be elucidated.Conclusions and outlook
The past 10 years have renewed our interest in PyV preva-
lence, biology, and pathology, and this has been a result of new
pathologies due to the introduction of new medical treatments
and the identiﬁcation of new PyVs, due to new techniques for
viral detection.
There have been changes in the disease epidemiology of both
JCV and BKV due to changes primarily in medical treatment. For
JCV, a decline of PML was observed in HIV-1 infected patients due
to highly active anti retroviral therapy, while PML has reemerged
in association with novel immunosuppressive therapies for auto-
immune diseases, e.g. in MS. For BKV, nephropathy after renal
transplantation has become more frequent especially in patients
treated with more potent immunosuppressive drugs.
In parallel eight new HPyVs have been identiﬁed due to new
techniques for viral detection. Notably, one MCPyV, was asso-
ciated with Merkel Cell Cancer, emphasizing the oncogenic
potential of HPyVs, while another TSV was associated with
trichdysplasia spinulosa a rare disease in immunosuppressed
individuals, again underlining the potential ability of HPyVs to
cause disease in the immunosuppressed. However, most impor-
tantly, the recent studies of HPyV discovery open up the possibi-
lity that a plethora of as yet unknown HPyVs exist, and it would
not be entirely surprising if they play additional roles in other
human diseases or cancer.
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